Author

Soeren Lykke Petersen

Observed names: Soeren Lykke Petersen, Soeren L Petersen

Institutions: Copenhagen University Hospital, Rigshospitalet

Observed institutions: Copenhagen University Hospital, Rigshospitalet

OpenAlex ID: A5110622259

Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial

2019 · Brenda M Sandmaier, Brian Kornblit, et al. · The Lancet Haematology · 115

Early Natural Killer Cell Reconstitution Predicts Overall Survival in T Cell–Replete Allogeneic Hematopoietic Stem Cell Transplantation

2016 · Lia Minculescu, Hanne Vibeke Marquart, et al. · Transplantation and Cellular Therapy · 64

Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations

2024 · Nigel H. Russell, Charlotte Wilhelm-Benartzi, et al. · Journal of Clinical Oncology · 49

C-Reactive Protein Levels at Diagnosis of Acute Graft-versus-Host Disease Predict Steroid-Refractory Disease, Treatment-Related Mortality, and Overall Survival after Allogeneic Hematopoietic Stem Cell Transplantation

2017 · Lia Minculescu, Brian Thomas Kornblit, et al. · Transplantation and Cellular Therapy · 16

Impact of comorbidities and body mass index on the outcomes of allogeneic hematopoietic cell transplantation in myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of EBMT

2024 · Nicola Polverelli, Edouard F. Bonneville, et al. · American Journal of Hematology · 13

Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy: Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party (IDWP) and the European Hematology Association (EHA) Lymphoma Group

2024 · Anne Mea Spanjaart, Per Ljungman, et al. · Leukemia · 7

Donor Lymphocyte Infusion Is a Feasible Way to Improve Survival in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Who Relapse after Allogeneic Stem Cell Transplantation

2023 · Lia Minculescu, Joanne Reekie, et al. · Acta Haematologica · 4

Real-World Outcomes of CD19-Targeted CAR T-Cell Therapy in Adult and Pediatric Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL): Insights from the GoCART Coalition on Behalf of the PDWP, ALWP, and CTIWP of the EBMT

2024 · Valentin Ortiz-Maldonado, Jacques-Emmanuel Galimard, et al. · Blood · 2

“Real World” Outcome of Hematopoietic Stem Cell Transplantation after CAR19 T Cell Therapy in Children and Adults with B-ALL: A Gocart Coalition Study on Behalf of the PDWP, ALWP, and Ctiwp of the EBMT

2024 · Giorgio Ottaviano, Anna Alonso-Saladrigues, et al. · Blood · 1

Immunotherapy refractoriness and early post-alloHCT relapse define ultra-high-risk B-ALL after CD19 CAR T-cell therapy

2026 · Valentín Ortiz-Maldonado, Jacques-Emmanuel Galimard, et al. · Blood Advances

Fertility management and outcomes after CAR T-cell therapy: an international survey from the Cellular Therapy and Immunobiology working party of the European Society for Blood and Marrow Transplantation

2026 · Giorgio Orofino, Isabel Sánchez-Ortega, et al. · EClinicalMedicine

Fertility after CAR T-Cell Therapy, a Survey on Management and Outcomes from the Cellular Therapy and Immunobiology Working Party of the EBMT

2026 · Giorgio Orofino, Isabel Sánchez-Ortega, et al. · SSRN Electronic Journal

Second Infusion of CAR T-Cells in Patients with Relapsed /Refractory B-Cell Acute Lymphoblastic Leukemia: Results from a Gocart Coalition Analysis on Behalf of the PDWP, ALWP, and Ctiwp of the EBMT

2024 · Susana Rives, Giorgio Ottaviano, et al. · Blood

Works count: 13

Citation count: 271

H-index: 6

I10-index: 5